Posters

      Application of Systems Pharmacology to Identify Exposure Response Markers in Peripheral Blood After Switching to a Candidate Modified Risk Tobacco Product: the Tobacco Heating System 2.1 (THS 2.1)

      Martin, F.; Talikka, M.; Haziza, C.; Ancerewicz, J. Ancerewicz.; Hoeng, J.; Peitsch, M. C.

      Conference date
      Mar 22, 2015
      Conference name
      Society of Toxicology (SOT) 2015
      Link to more information
      Topic
      Summary

      Establishing exposure-response markers is imperative for the assessment of candidate modified risk tobacco products (MRTPs) against conventional combustible cigarettes (CC). Biomarkers derived from the primary site, such as the airway, require invasive sampling, whereas blood offers a non-invasive alternative for the general population. Various diseases and exposures, including cigarette smoke, have been shown to alter the molecular profile of the blood. To identify exposure-response relationships, we have conducted a whole genome Affymetrix microarray analyses from blood derived from a clinical study comparing smokers switching from CC to candidate MRTP THS 2.1, and from smokers who continued smoking their own CC for 5 consecutive days. The open-label, randomized, controlled, 2-arm parallel group recruited 42 healthy smokers of both genders, aged between 23 and 65 years and was conducted according to Good Clinical Practices (GCP) and is registered on ClinicalTrials.gov, number NCT01780714. By analyzing the whole blood transcriptome of the study subjects and leveraging previously identified genes that exhibited a response to smoking in blood, we derived a classification tool using statistical learning methods. The classifier consisted of eight genes and differentiated users of THS 2.1 from smokers of CC with a specificity and sensitivity of 0.81 and 0.74, respectively. Several of these genes have been previously reported to be differentially expressed in the blood of smokers as compared to never smokers. In conclusion, our systems pharmacology approach showed that the impact of switching to THS 2.1 can be detected in 5 days in whole blood transcriptome, thus providing a sensitive and non-invasive tool to assess exposure-response. These data alone do not substantiate reduced risk, and a range of further studies, including clinical studies, are being conducted on MRTPs. 

      Related Publications

      Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking

      Clinical

      Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

      Clinical

      Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

      Clinical

      Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

      Clinical

      Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

      Clinical

      Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.